<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198184">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510718</url>
  </required_header>
  <id_info>
    <org_study_id>S-3100-1-01</org_study_id>
    <nct_id>NCT00510718</nct_id>
    <nct_alias>NCT00513812</nct_alias>
  </id_info>
  <brief_title>A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medivation, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to
      treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional
      patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients
      who tolerate the drug and do not progress will be allowed to continue to look for PSA
      response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, uncontrolled, dose-escalation study with dose-expansion at
      doses determined to be tolerated. Patients who tolerate the drug and do not progress will be
      allowed to continue treatment. The study endpoints are safety and tolerability and
      pharmacokinetics. PSA values will also be collected to look for PSA response.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, PSA response</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Hormone Refractory Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDV3100</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDV3100</intervention_name>
    <description>MDV3100 daily until progression or dose-limiting toxicity</description>
    <arm_group_label>1</arm_group_label>
    <other_name>enzalutamide</other_name>
    <other_name>Xtandi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate;

          2. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH)
             analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration);

          3. Progressive disease after medical or surgical castration,

        Exclusion Criteria:

        1. Metastases in the brain or active epidural disease. (Note: patients with treated
        epidural disease are allowed);
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Medivation, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 18, 2017</lastchanged_date>
  <firstreceived_date>July 31, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <keyword>Hormone</keyword>
  <keyword>Refractory</keyword>
  <keyword>Castration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
